The Individualized Medicine Biobank for Bipolar Disorder is intended to serve as a resource for the bipolar research community. This biobank will be open to collaborations after a three-year infrastructure development.
Researchers are establishing a large-scale biobank of Bipolar Type I and II Disorder, collecting both biologic samples and clinical data from 2,000 individuals ages 18-80. This is a multi-site endeavor, with Mayo Clinic Minnesota serving as the primary project site. Researchers at Mayo Clinic will collaborate with other researchers at the University of Minnesota, Lindner Center of Hope (Cincinnati, Ohio) as well as the Mayo Clinic sites of Arizona and Florida.
We are also collaborating with the Mayo Health System, including Austin Medical Center. By establishing the infrastructure of this data-rich biobank, researchers hope to facilitate studies on disease risk and pharmacogenomic probes utilizing state-of-the-art research technology.
The Individualized Medicine Biobank for Bipolar Disorder has built a community advisory board to help guide us in this critical early phase development. The identification of genetic risk factors associated with disease onset can potentially lead to early interventional treatment in at-risk patients. This is particularly important in Bipolar Disorder, as the onset of any treatment is often delayed by more than a decade and those individuals with the earliest illness onset generally have poor outcomes and the longest delays to first treatment.
Additionally, identification of pharmacogenomic predictors of treatment response could provide greater selectivity to treatment recommendations, as well as help prevent such serious adverse events as antidepressant induced mania.
The Bipolar Biobank is supported by a generous gift from a private benefactor.
Face It Foundation 2011 Bike Tour